Get the Stockscreener App
12.91
2.95%
0.37
After Hours:
12.66
-0.25
-1.94%
Myriad Genetics Inc stock is traded at $12.91, with a volume of 1.66M.
It is up +2.95% in the last 24 hours and down -5.28% over the past month.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$12.54
Open:
$12.6
24h Volume:
1.66M
Relative Volume:
1.66
Market Cap:
$1.18B
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-9.9308
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+1.18%
1M Performance:
-5.28%
6M Performance:
-53.58%
1Y Performance:
-42.65%
1-Day Range:
$12.36
$13.10
1-Week Range:
$12.22
$13.17
52-Week Range:
$12.04
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
12.91 | 1.18B | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
606.46 | 231.78B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
223.07 | 159.92B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
151.36 | 43.41B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.74 | 36.50B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
423.99 | 34.79B | 3.84B | 866.24M | 792.60M | 10.37 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
The Goldman Sachs Group Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $18.00 - MarketBeat
Cancer Diagnostics Market Top Companies StudyDanaher - openPR
(MYGN) Trading Advice - Stock Traders Daily
Myria and Beacher’s Madhouse to Bring an Unforgettable Spectacle to New Orleans During Big Game Weekend - GlobeNewswire Inc.
Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? - Yahoo Finance
MYGN Stock Gains Following the Launch of Know More Sooner - MSN
Myriad Genetics (NASDAQ:MYGN) Reaches New 12-Month LowHere's Why - MarketBeat
Myriad Genetics stock hits 52-week low at $12.16 amid market challenges - Investing.com
Myriad Genetics Launches 'Know More Sooner' Platform to Expand Prenatal Genetic Testing Access - StockTitan
FY2024 EPS Estimates for Myriad Genetics Raised by Analyst - MarketBeat
Genomic Biomarker Market Growth in Future Scope 2025-2032 | - openPR
Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance - MarketBeat
Stephens Reaffirms Equal Weight Rating for Myriad Genetics (NASDAQ:MYGN) - MarketBeat
Myriad Genetics stock hits 52-week low at $12.85 amid market challenges - Investing.com Australia
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha
Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $24.27 - MarketBeat
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025 - Marketscreener.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of “Hold” from Analysts - Defense World
Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c - MSN
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 2024 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance - MarketBeat
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial ... - The Bakersfield Californian
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6%Here's What Happened - MarketBeat
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Relationship Genetic Tests Market Report 2024, Featuring - GlobeNewswire
Relationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and More - Yahoo Finance
Myriad Genetics FY2024 EPS Estimate Increased by Scotiabank - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Nordea Investment Management AB - MarketBeat
MYGN Stock Gains Following Collaboration With Hannah Storm - Yahoo Finance
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History - The Manila Times
Myriad Genetics (NASDAQ:MYGN) Rating Increased to Buy at StockNews.com - MarketBeat
Myriad Genetics Partners with ESPN's Hannah Storm to Champion Breast Cancer Risk Testing - StockTitan
PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity - Yahoo Finance UK
Myriad Genetics and MD Anderson Launch Strategic Partnership to Advance MRD Assays - Zenopa
UPDATEMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Myriad Genetics to Present at J.P. Morgan Healthcare Conference 2024 with Live Webcast - StockTitan
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued - Simply Wall St
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):